Join Sagimet Biosciences for a virtual key opinion leader (KOL) event featuring Neal Bhatia, MD (Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego), who will join company management to review positive efficacy and tolerability results from a Phase 3 clinical trial evaluating denifanstat for the treatment of moderate to severe acne vulgaris in China conducted by license partner Ascletis.

Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor. In the Phase 3 study, denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated. The robust Phase 3 results underline the potential of FASN inhibition as a novel mechanism of action to address acne, a condition that impacts more than 50 million people in the U.S. Management will also discuss the Company’s recently initiated Phase 1 first in-human study with its second oral FASN inhibitor drug candidate, TVB-3567, which is planned to be developed for acne in the U.S.

A live question and answer session will follow the formal presentations.